Literature DB >> 25086031

Phosphorylation of Cdc42 effector protein-4 (CEP4) by protein kinase C promotes motility of human breast cells.

Xin Zhao1, Susan A Rotenberg2.   

Abstract

Cdc42 effector protein-4 (CEP4) was recently identified by our laboratory to be a substrate of multiple PKC isoforms in non-transformed MCF-10A human breast cells. The significance of phosphorylated CEP4 to PKC-stimulated motility of MCF-10A cells was evaluated. Single site mutants at Ser residues embedded in potential PKC consensus sites (Ser(18), Ser(77), Ser(80), and Ser(86)) were individually replaced with Asp residues to simulate phosphorylation. Following expression in weakly motile MCF-10A cells, the S18D and S80D mutants each promoted increased motility, and the double mutant (S18D/S80D) produced a stronger effect. MS/MS analysis verified that Ser(18) and Ser(80) were directly phosphorylated by PKCα in vitro. Phosphorylation of CEP4 severely diminished its affinity for Cdc42 while promoting Rac activation and formation of filopodia (microspikes). In contrast, the phosphorylation-resistant double mutant S18A/S80A-CEP4 blocked CEP4 phosphorylation and inhibited motility of MCF-10A cells that had been stimulated with PKC activator diacylglycerol lactone. In view of the dissociation of phospho-CEP4 from Cdc42, intracellular binding partners were explored by expressing each CEP4 double mutant from a tandem affinity purification vector followed by affinity chromatography, SDS-PAGE, and identification of protein bands evident only with S18D/S80D-CEP4. One binding partner was identified as tumor endothelial marker-4 (TEM4; ARHGEF17), a guanine nucleotide exchange factor that is involved in migration. In motile cells expressing S18D/S80D-CEP4, knockdown of TEM4 inhibited both Rac activation and motility. These findings support a model in which PKC-mediated phosphorylation of CEP4 at Ser(18) and Ser(80) causes its dissociation from Cdc42, thereby increasing its affinity for TEM4 and producing Rac activation, filopodium formation, and cell motility.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Actin; Breast Cancer; GTPase; Guanine Nucleotide Exchange Factor (GEF); Protein Kinase C, Cdc42, Rac, Mutant; Protein Phosphorylation; Protein Purification

Mesh:

Substances:

Year:  2014        PMID: 25086031      PMCID: PMC4162185          DOI: 10.1074/jbc.M114.577783

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  MSE55, a Cdc42 effector protein, induces long cellular extensions in fibroblasts.

Authors:  P D Burbelo; D M Snow; W Bahou; S Spiegel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Motility and invasion are differentially modulated by Rho family GTPases.

Authors:  J Banyard; B Anand-Apte; M Symons; B R Zetter
Journal:  Oncogene       Date:  2000-01-27       Impact factor: 9.867

Review 3.  Protein kinase C as a therapeutic target.

Authors:  Beverly A Teicher
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

4.  Consensus sequences as substrate specificity determinants for protein kinases and protein phosphatases.

Authors:  P J Kennelly; E G Krebs
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

Review 5.  Structural basis of protein kinase C isoform function.

Authors:  Susan F Steinberg
Journal:  Physiol Rev       Date:  2008-10       Impact factor: 37.312

Review 6.  The Par3/Par6/aPKC complex and epithelial cell polarity.

Authors:  Jia Chen; Mingjie Zhang
Journal:  Exp Cell Res       Date:  2013-03-25       Impact factor: 3.905

Review 7.  Preclinical and clinical development of novel agents that target the protein kinase C family.

Authors:  Maria Serova; Aïda Ghoul; Karim A Benhadji; Esteban Cvitkovic; Sandrine Faivre; Fabien Calvo; François Lokiec; Eric Raymond
Journal:  Semin Oncol       Date:  2006-08       Impact factor: 4.929

8.  Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells.

Authors:  Yufeng Zuo; Yuexiu Wu; Chandan Chakraborty
Journal:  J Cell Physiol       Date:  2012-04       Impact factor: 6.384

9.  Phosphorylation of alpha6-tubulin by protein kinase Calpha activates motility of human breast cells.

Authors:  Thushara P Abeyweera; Xiangyu Chen; Susan A Rotenberg
Journal:  J Biol Chem       Date:  2009-04-29       Impact factor: 5.157

10.  Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells.

Authors:  Paige J Baugher; Lakshmi Krishnamoorthy; Janet E Price; Surangani F Dharmawardhane
Journal:  Breast Cancer Res       Date:  2005-09-30       Impact factor: 6.466

View more
  6 in total

1.  A novel and selective inhibitor of PKC ζ potently inhibits human breast cancer metastasis in vitro and in mice.

Authors:  Jing Wu; Shuye Liu; Zhijuan Fan; Lei Zhang; Yaqiong Tian; Rui Yang
Journal:  Tumour Biol       Date:  2016-01-05

2.  Knockdown of UbcH10 enhances the chemosensitivity of dual drug resistant breast cancer cells to epirubicin and docetaxel.

Authors:  Cheng Wang; Yun-Hao Pan; Ming Shan; Ming Xu; Jia-Lin Bao; Li-Ming Zhao
Journal:  Int J Mol Sci       Date:  2015-03-02       Impact factor: 5.923

Review 3.  The Borg family of Cdc42 effector proteins Cdc42EP1-5.

Authors:  Aaron J Farrugia; Fernando Calvo
Journal:  Biochem Soc Trans       Date:  2016-12-15       Impact factor: 5.407

4.  Cdc42 regulates Cdc42EP3 function in cancer-associated fibroblasts.

Authors:  Aaron J Farrugia; Fernando Calvo
Journal:  Small GTPases       Date:  2016-06-01

5.  Regulation of dendrite growth by Cdc42 effector protein‑4 in hippocampal neurons in vitro.

Authors:  Lei Hou; Lufeng Wang; Zhijie Zhao; Wei Xu; Yang Wang; Gang Cui
Journal:  Mol Med Rep       Date:  2022-02-16       Impact factor: 2.952

6.  CDC42EP5/BORG3 modulates SEPT9 to promote actomyosin function, migration, and invasion.

Authors:  Aaron J Farrugia; Javier Rodríguez; Jose L Orgaz; María Lucas; Victoria Sanz-Moreno; Fernando Calvo
Journal:  J Cell Biol       Date:  2020-09-07       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.